SAMN30223172
External Id
dbGaP
INSDC center name
2022-08-10T02:53:15.957Z
INSDC first public
2022-09-22T02:57:15.540Z
INSDC last update
SRS15029609
INSDC secondary accession
live
INSDC status
Generic
NCBI submission model
Generic.1.0
NCBI submission package
SRS15029609
SRA accession
DNA
analyte type
NCI_LA_HNSCC_Everolimus
biospecimen repository
09266_005_1_T_000018C1DL
biospecimen repository sample id
LARYNX
body site
phs002986
gap_accession
1
gap_consent_code
GRU
gap_consent_short_name
5064293
gap_sample_id
4298122
gap_subject_id
Yes
is tumor
Homo sapiens
http://purl.obolibrary.org/obo/NCBITaxon_9606
organism
male
sex
Case Set
study design
Squamous Cell Carcinoma of Head and Neck
study disease
A Randomized Multi-Institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck
study name
Yes
subject is affected
09266_005_1_T_000018C1DL
submitted sample id
005
submitted subject id
NCI_LA_HNSCC_Everolimus
submitter handle
Squamous Cell Carcinoma of Head and Neck tumor DNA sample from LARYNX of a human male participant in the dbGaP study A Randomized Multi-Institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck
title